The human intestinal cytochrome P450 "pie" - PubMed (original) (raw)
The human intestinal cytochrome P450 "pie"
Mary F Paine et al. Drug Metab Dispos. 2006 May.
Abstract
Cytochromes P450 (P450s) 3A, 2C, and 1A2 constitute the major "pieces" of the human liver P450 "pie" and account, on average, for 40, 25, and 18%, respectively, of total immunoquantified P450s (J Pharmacol Exp Ther 270:414-423, 1994). The P450 profile in the human small intestine has not been fully characterized. Therefore, microsomes prepared from mucosal scrapings from the duodenal/jejunal portion of 31 human donor small intestines were analyzed by Western blot using selective P450 antibodies. P450s 3A4, 2C9, 2C19, and 2J2 were detected in all individuals and ranged from 8.8 to 150, 2.9 to 27, <0.6 to 3.9, and <0.2 to 3.1 pmol/mg, respectively. CYP2D6 was detected in 29 individuals and ranged from <0.2 to 1.4 pmol/mg. CYP3A5 was detected readily in 11 individuals, with a range (average) of 4.9 to 25 (16) pmol/mg that represented from 3 to 50% of total CYP3A (CYP3A4 + CYP3A5) content. CYP1A1 was detected readily in three individuals, with a range (average) of 3.6 to 7.7 (5.6) pmol/mg. P450s 1A2, 2A6, 2B6, 2C8, and 2E1 were not or only faintly detected. As anticipated, average CYP3A content (50 pmol/mg) was the highest. Excluding CYP1A1, the remaining enzymes had the following rank order: 2C9 > 2C19 > 2J2 > 2D6 (8.4, 1.1, 0.9, and 0.5 pmol/mg, respectively). Analysis of a pooled preparation of the 31 donor specimens substantiated these results. In summary, as in the liver, large interindividual variation exists in the expression levels of individual P450s. On average, CYP3A and CYP2C9 represents the major pieces of the intestinal P450 pie, accounting for 80 and 15%, respectively, of total immunoquantified P450s.
Figures
FIG. 1
Western blot showing the specificity of the anti-CYP2C19 polyclonal antibody after a typical exposure for the detection of CYP2C9 and CYP2C19 (A) or a prolonged exposure (B). Except for the recombinant CYP2Cs, which represent equimolar amounts (200 fmol), the amount of recombinant P450 represents the highest amount used for the generation of the calibration curves for quantification (P450s 1A1, 2D6, 2J2, 3A4, and 3A5) or detection (P450s 2A6, 2B6, and 2E1) in human intestinal microsomes: 100, 80, 100, 600, 400, 80, 150, and 40 fmol, respectively. Each human liver microsomal (HLM) preparation represents 2 µg of microsomal protein. HL-150 was known to contain CYP3A5.
FIG. 2
Western blots of pooled (n = 31, except where noted) human intestinal microsomal preparations (HIM) showing the presence or absence of various P450s. The amount of recombinant enzymes (standards) ranged from 100 to 12.5 (CYP1A1), 80 to 10 (CYP2A6), 150 to 18.8 (CYP2B6), 600 to 75 (CYP2C9), 200 to 25 (CYP2C19), 80 to 10 (CYP2D6), 40 to 5 (CYP2E1), 100 to 12.5 (CYP2J2), 600 to 75 (CYP3A4), and 400 to 50 (CYP3A5) fmol. The pooled HIM represent 40 (P450s 1A1, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, and P2J2), 5 (CYP3A4), or 10 (CYP3A5) µg of microsomal protein. Each human liver microsomal (HLM) preparation represents 2 (CYP2E1), 5 (P450s 2A6, 2D6, 3A4, and 2J2), 10 (1A1, 2C9, 2C19, and 3A5), or 20 (CYP2B6) µg of microsomal protein. HL-150 was known to contain CYP3A5.
FIG. 3
The average human proximal small intestinal and hepatic P450 pies. The percent contributions of individual P450 enzymes are based on total immunoquantified P450 content. The values for the liver pie were derived from Shimada et al.(1994).
Similar articles
- A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism.
Gelboin HV, Krausz KW, Shou M, Gonzalez FJ, Yang TJ. Gelboin HV, et al. Pharmacogenetics. 1997 Dec;7(6):469-77. doi: 10.1097/00008571-199712000-00005. Pharmacogenetics. 1997. PMID: 9429232 - Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
Kudo S, Odomi M. Kudo S, et al. Eur J Clin Pharmacol. 1998 May;54(3):253-9. doi: 10.1007/s002280050455. Eur J Clin Pharmacol. 1998. PMID: 9681669 - Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H, White RB, Stevens JC. Heyn H, et al. Drug Metab Dispos. 1996 Sep;24(9):948-54. Drug Metab Dispos. 1996. PMID: 8886603 - Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM, Schwab M. Zanger UM, et al. Pharmacol Ther. 2013 Apr;138(1):103-41. doi: 10.1016/j.pharmthera.2012.12.007. Epub 2013 Jan 16. Pharmacol Ther. 2013. PMID: 23333322 Review. - Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.
Gelboin HV, Krausz K. Gelboin HV, et al. J Clin Pharmacol. 2006 Mar;46(3):353-72. doi: 10.1177/0091270005285200. J Clin Pharmacol. 2006. PMID: 16490812 Review.
Cited by
- Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.
Helland T, Alsomairy S, Lin C, Søiland H, Mellgren G, Hertz DL. Helland T, et al. J Pers Med. 2021 Mar 13;11(3):201. doi: 10.3390/jpm11030201. J Pers Med. 2021. PMID: 33805613 Free PMC article. Review. - Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content.
Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Emoto C, et al. CPT Pharmacometrics Syst Pharmacol. 2013 Jul 24;2(7):e59. doi: 10.1038/psp.2013.33. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 23884207 Free PMC article. - Human intestinal organoid-derived PDGFRα + mesenchymal stroma enables proliferation and maintenance of LGR4 + epithelial stem cells.
Chen J, Horiuchi S, Kuramochi S, Kawasaki T, Kawasumi H, Akiyama S, Arai T, Morinaga K, Kimura T, Kiyono T, Akutsu H, Ishida S, Umezawa A. Chen J, et al. Stem Cell Res Ther. 2024 Jan 17;15(1):16. doi: 10.1186/s13287-023-03629-5. Stem Cell Res Ther. 2024. PMID: 38229108 Free PMC article. - Cytochrome P450 3A4 suppression by epimedium and active compound kaempferol leads to synergistic anti-inflammatory effect with corticosteroid.
Li K, Yu XH, Maskey AR, Musa I, Wang ZZ, Garcia V, Guo A, Yang N, Srivastava K, Dunkin D, Li JX, Guo L, Cheng YC, Yuan H, Tiwari R, Li XM. Li K, et al. Front Pharmacol. 2023 Jan 30;13:1042756. doi: 10.3389/fphar.2022.1042756. eCollection 2022. Front Pharmacol. 2023. PMID: 36793921 Free PMC article. - Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids.
Kamble SH, Sharma A, King TI, Berthold EC, León F, Meyer PKL, Kanumuri SRR, McMahon LR, McCurdy CR, Avery BA. Kamble SH, et al. Toxicol Lett. 2020 Feb 1;319:148-154. doi: 10.1016/j.toxlet.2019.11.005. Epub 2019 Nov 7. Toxicol Lett. 2020. PMID: 31707106 Free PMC article.
References
- de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther. 1990;253:387–394. - PubMed
- Fontana RJ, Lown KS, Paine MF, Fortlage L, Santella RM, Felton JS, Knize MG, Greenberg A, Watkins PB. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A and P-glycoprotein levels in healthy volunteers. Gastroenterology. 1999;117:89–98. - PubMed
- Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996;333:447–458. - PubMed
- Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, Funae Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther. 2002;300:298–304. - PubMed
- Hu Y, Krausz K, Gelboin HV, Kupfer D. CYP2C subfamily, primarily CYP2C9, catalyses the enantioselective demethylation of the endocrine disruptor pesticide methoxychlor in human liver microsomes: use of inhibitory monoclonal antibodies in P450 identification. Xenobiotica. 2004;34:117–132. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- Z01 ES025034-13/Intramural NIH HHS/United States
- GM38149/GM/NIGMS NIH HHS/United States
- GM32165/GM/NIGMS NIH HHS/United States
- P01 GM032165/GM/NIGMS NIH HHS/United States
- R37 GM038149/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials